Opiant approved for NASDAQ listing

nasdaq_000015821689_LRG.jpg

Shares of Opiant Pharmaceuticals were approved for listing on the Nasdaq Capital Market at the opening tomorrow (August 29) under the symbol, OPNT.  The company’s common stock had traded on the OTCQB Marketplace since 2007.

“Our listing on Nasdaq represents a major corporate milestone for Opiant as we continue to progress into a leading player in the treatment of addictions,” Dr. Roger Crystal, CEO, said in a statement.  

“We believe that trading on Nasdaq will expand our visibility, broaden and diversify our stockholder base, provide better liquidity and ultimately contribute to our ability to increase stockholder value,” he added.